**Supplementary table.** Associated medication of secondary hyperparathyroidism outcome in each of the two groups separately

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Month -3** | **Baseline** | **Month 3** | **Month 6** | **P** |
| **Active Vitamin D dose (mcg/week)**  **Adherents Cinacalcet (n=18)**  **Non-adherents Cinacalcet (n=11)** | 2.12 ± 2.34  2.64 ± 2.11  P=0.540 | 2.41 ± 2.45  2.64 ± 2.11  P=0.779 | 2.76 ± 2.44  2.82 ± 1.99  P=0.952 | 3.12 ± 2.69  2.64 ± 2.29  P=0.629 | NS  NS |
| **Phosphate bindings with calcium**  **(pills/d)**  **Adherents Cinacalcet (n=18)**  **Non-adherents Cinacalcet (n=11)** | 1.53 ± 1.88  1.36 ± 1.96  P=0.735 | 1.82 ± 1.85  1.45 ± 2.07  P=0.557 | 1.88 ± 1.83  1.55 ± 2.21  P=0.665 | 2.00 ± 1.90  1.55 ± 2.21  P=0.567 | NS  NS |

ANOVA (repeated measures)